

## Newbury Pharmaceuticals Q4 Report - Bolstered business

Redeye provides a research update following the Q4 report published by Newbury yesterday. We make some slight adjustments to our estimates for net sales and include the recent loan agreement in our model. However, we reiterate our fair value range with a base case valuation of SEK8.5 as we maintain a positive outlook on the case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Newbury Pharmaceuticals Q4 Report - Bolstered business](#)